Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (mCRC): An age-stratified analysis.
Authors
Zdravko Vassilev
Bayer HealthCare Pharmaceuticals, Whippany, NJ;
Zdravko Vassilev , Xiaozhou Fan , Helene Ostojic , Julie Xu , Afsaneh Barzi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
123456789
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 64)
DOI
10.1200/JCO.2023.41.4_suppl.64
Abstract #
64
Poster Bd #
D1
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Front-line use of FOLFOXIRI plus bevacizumab and subsequent therapies in metastatic colorectal cancer (mCRC).
First Author: Afsaneh Barzi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Myostatin/activin pathway gene expression and single nucleotide polymorphisms (SNPs) in metastatic colorectal cancer (mCRC).
First Author: Karam Ashouri
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Tumor response of FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: The subgroup-analysis of DEEPER trial (JACCRO CC-13).
First Author: Hironaga Satake
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz